Spinal Cord Injury Neuroprotection With Glyburide
ConditionAcute Spinal Cord Injury
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-80
SponsorFrancis Farhadi
About this trial
To assess the safety and efficacy of using oral Glyburide (Diabeta) as a neuroprotective agent in patients with acute cervical or thoracic traumatic spinal cord injury.
Eligibility criteria
Qualifiers
No life threatening injuries resulting from the traumatic accident
No evidence of sepsis
Acute cervical or thoracic SCI with ASIA Impairment Scale Grade A, B, or C od admission.
Non-penetrating SCI at neurologic level from C2 to C8 or T1 to T12
Disqualifiers
Unconsciousness or other mental impairment that prevents neurological assessment within the first 8 hours
Acute SCI with ASIA Impairment Scale grade D or E
Currently involved in another non-observational SCI research study or receiving another investigational drug
History of hypersensitivity to sulfonylureas, in particular glyburide, or any of its components
Trial design
Treatments tested in this trial
- GlyBURIDE Oral Tablet
Treatment groups
12 Participants
are divided into 1 treatment groupSponsors and collaborators
Francis Farhadi
Lead sponsor
University of Kentucky
Sponsor institution
Source ClinicalTrials.gov